Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration

V Daien; V Nguyen; RW Essex; N Morlet; D Barthelmes; MC Gillies; A Hunt; C Dayajeewa; A Hunyor; S Fraser-Bell; C Younan; A Fung; R Guymer; D Louis; J Arnold; D Chan; H Cass; A Harper; J O'Day; M Daniell; A Field; LP Chow; A Cohn; S Young; S Lal; R Ferrier; R Barnes; A Thompson; A Vincent; L Manning; S Lake; R Phillips; M Perks; JY Chen; J Landers; Niladri; G Banerjee; B Swamy; P Windle; A Dunlop; KC Tang; I McLean; A Amini; G Clark; I McAllister; F Chen; D Squirrell; C Ng; P Hinchcliffe; R Barry; J Ah-Chan; H Steiner; M Morgan; C Thompson; J Game; N Murray

Journal article

Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration

V Daien, V Nguyen, RW Essex, N Morlet, D Barthelmes, MC Gillies, A Hunt, C Dayajeewa, A Hunyor, S Fraser-Bell, C Younan, A Fung, R Guymer, D Louis, J Arnold, D Chan, H Cass, A Harper, J O'Day, M Daniell Show all

Ophthalmology | ELSEVIER SCIENCE INC | Published : 2018

DOI: 10.1016/j.ophtha.2017.07.005

Abstract

Purpose To assess the incidence, cumulative rate, and long-term outcomes of infectious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothelial growth factor (VEGF) agents. Design Database study, prospectively designed. Participants Treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) tracked by the Fight Retinal Blindness! (FRB!) registry that commenced anti-VEGF therapy between January 1, 2006, and November 30, 2016. Methods Cumulative rate of endophthalmitis and survival curves were measured using Cox-proportional hazards models. Locally weighted scatterplot smoothing curves were used to display visual acuity (VA). Main O..

View full abstract

University of Melbourne Researchers

Robyn Guymer Author

Alex Harper Author

Mark Daniell Author

Grants

Funding Acknowledgements

The author(s) made the following disclosures: V.D.: Research grant of the French Society of Ophthalmology. M.C.G.: Sydney Medical Foundation Fellow; Support - National Health and Medical Research Council practitioner fellowship. D.B.: Support - Walter and Gertrud Siegenthaler Foundation Zurich, Switzerland, and the Swiss National Foundation. Supported by grants from the Royal Australian NZ College of Ophthalmologists Eye Foundation (2007-2009), the National Health and Medical Research Council, Australia (2010-2012), and the Macular Disease Foundation, Australia. Funding was provided by Novartis and Bayer. These supporting organizations had no role in the design or conduct of the research.